Encouraging Results from First HIV Vaccine Trial

News Desk
Islamabad: After the results of the second phase of the trial of the HIV vaccine developed by the British pharmaceutical company were also encouraging, there is hope that the world will soon get the first HIV vaccine.

According to the Reuters news agency, the second phase of the vaccine developed by the British pharmaceutical company GlaxoSmithKline (GSK) in collaboration with other companies also revealed that it did not spread the HIV virus.
The company has developed a vaccine combining two existing HIV drugs, cabotegravir and rilpivirine, which experts say is more effective than pills.
The company has named the vaccine Cabenuva, which is given to the patient as an injection.
The vaccine was tested in 31 different locations around the world and two doses of the vaccine were administered every month to people who were already infected with HIV.
Infected volunteers were given the vaccine twice a month for a year, after which they were tested for the disease, which showed that their HIV levels were very low or weakened and that they had passed on to another person. The virus is not transmitted.
According to experts, the said vaccine is not designed to eliminate HIV but to prevent the spread of HIV, the vaccine does not eliminate the disease but prevents it from growing and spreading.
After the successful results of the second phase of the vaccine trial, it is expected that the final and larger trial will be successful and soon the world will get the first HIV vaccine.
At least two previous HIV vaccine trials had failed, meaning the vaccines had no role in preventing the disease or reducing its spread.